Nonalcoholic fatty liver disease: From steatosis to cirrhosis
暂无分享,去创建一个
[1] J. Mckenney,et al. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.
[2] P. Christoffersen,et al. Liver histology in a 'normal' population--examinations of 503 consecutive fatal traffic casualties. , 1977, Scandinavian journal of gastroenterology.
[3] J. Parks,et al. Mitochondrial abnormalities in non-alcoholic steatohepatitis. , 1999, Journal of hepatology.
[4] R O Morgan,et al. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study , 2005, Gut.
[5] J. Jessurun,et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. , 2005, The Journal of clinical investigation.
[6] G. Gores,et al. Ursodeoxycholic acid or clofibrate in the treatment of non‐alcohol‐induced steatohepatitis: A pilot study , 1996, Hepatology.
[7] H. Bonkovsky,et al. Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. , 1999, Journal of hepatology.
[8] A. Lonardo,et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver , 2004, Hepatology.
[9] E. Fassio,et al. Natural history of nonalcoholic steathepatitis: A longitudinal study of repeat liver biopsies , 2004, Hepatology.
[10] K. Feingold,et al. TNF-α is not the cause of fatty liver disease in obese diabetic mice , 2001, Nature Medicine.
[11] F. Schaffner,et al. Effect of weight reduction on hepatic abnormalities in overweight patients. , 1990, Gastroenterology.
[12] K. Petersen,et al. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. , 2004, The New England journal of medicine.
[13] S. Thung,et al. The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 1999 by The Endocrine Society Liver Pathology and the Metabolic Syndrome X in , 2022 .
[14] I. Leclercq,et al. NF-kappaB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis. , 2005, Gastroenterology.
[15] F. Kinjo,et al. Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease. , 2005, World journal of gastroenterology.
[16] Y. Iwamoto,et al. Prevalence of non‐alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults , 2005, Diabetic medicine : a journal of the British Diabetic Association.
[17] Erick M Remer,et al. The utility of radiological imaging in nonalcoholic fatty liver disease. , 2002, Gastroenterology.
[18] J. Dixon,et al. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. , 2001, Gastroenterology.
[19] M. Czaja,et al. Hepatocyte CYP2E1 Overexpression and Steatohepatitis Lead to Impaired Hepatic Insulin Signaling* , 2005, Journal of Biological Chemistry.
[20] S. Sanderson,et al. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. , 2005, Journal of hepatology.
[21] P. Hayashi,et al. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study , 2003, American Journal of Gastroenterology.
[22] Jonathan C. Cohen,et al. Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity , 2004, Hepatology.
[23] N. Chalasani,et al. Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis , 2003, Hepatology.
[24] S. Shoelson,et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB , 2005, Nature Medicine.
[25] Douglas L. Rothman,et al. Mitochondrial Dysfunction in the Elderly: Possible Role in Insulin Resistance , 2003, Science.
[26] A. Clouston,et al. Steatosis: Co‐factor in other liver diseases , 2005, Hepatology.
[27] T. Valle,et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. , 2001, The New England journal of medicine.
[28] Mauro Salizzoni,et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. , 2002, Gastroenterology.
[29] J. Ludwig,et al. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. , 2002, Journal of hepatology.
[30] L. Rovati,et al. Efficacy and Safety of Oral Betaine Glucuronate in Non-alcoholic Steatohepatitis , 2000, Arzneimittelforschung.
[31] Hajime Isomoto,et al. Fatty liver in non‐alcoholic non‐overweight Japanese adults: Incidence and clinical characteristics , 2002, Journal of gastroenterology and hepatology.
[32] J. Ludwig,et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. , 1980, Mayo Clinic proceedings.
[33] Z. Younossi,et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. , 1999, Gastroenterology.
[34] J. Dixon,et al. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss , 2004, Hepatology.
[35] J. Clore,et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[36] K. Batts,et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis , 1999, Hepatology.
[37] R. McCuskey,et al. Hepatic microvascular dysfunction during evolution of dietary steatohepatitis in mice , 2004, Hepatology.
[38] S. Caldwell,et al. Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. , 2000, The American journal of medicine.
[39] J. Horton,et al. Molecular mediators of hepatic steatosis and liver injury. , 2004, The Journal of clinical investigation.
[40] V. de Lédinghen,et al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study , 2005, Gut.
[41] K. Tanikawa,et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. , 1997, Journal of hepatology.
[42] P. Bedossa,et al. Fibrosis in Patients with Chronic Hepatitis C: Detection and Significance , 2000, Seminars in liver disease.
[43] P. Hayashi,et al. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis , 2003, American Journal of Gastroenterology.
[44] C. Day,et al. Steatohepatitis: a tale of two "hits"? , 1998, Gastroenterology.
[45] A. Scheen,et al. Liver abnormalities in severely obese subjects: Effect of drastic weight loss after gastroplasty , 1998, International Journal of Obesity.
[46] K. Lindor,et al. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study , 2001, American Journal of Gastroenterology.
[47] R. Fisher,et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values , 2003, Hepatology.
[48] S. Jang,et al. The effect of donor weight reduction on hepatic steatosis for living donor liver transplantation , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[49] G. Marchesini,et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver , 2004, Hepatology.
[50] I. Leclercq,et al. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. , 2000, The Journal of clinical investigation.
[51] F. Schaffner,et al. Fatty liver hepatitis and cirrhosis in obese patients. , 1979, The American journal of medicine.
[52] N. Weiss,et al. Contribution of metabolic factors to alanine aminotransferase activity in persons with other causes of liver disease. , 2005, Gastroenterology.
[53] B. Neuschwander‐Tetri,et al. Nonalcoholic steatohepatitis: an expanded clinical entity. , 1994, Gastroenterology.
[54] A. J. Bourne,et al. Non‐alcoholic steatohepatitis in children and adolescents , 2000, The Medical journal of Australia.
[55] S. Grundy,et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. , 2005, American journal of physiology. Endocrinology and metabolism.
[56] P. Angulo,et al. Nonalcoholic fatty liver disease. , 2002, Revista de gastroenterologia de Mexico.
[57] P. Bennett,et al. Diabetes duration and cause-specific mortality in the Verona Diabetes Study. , 2000, Diabetes care.
[58] Yu Wang,et al. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. , 2003, The Journal of clinical investigation.
[59] H. Yoshimatsu,et al. Adiponectin protects LPS-induced liver injury through modulation of TNF-alpha in KK-Ay obese mice. , 2004, Hepatology.
[60] I. Wanless,et al. The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases: a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis. , 2004, Seminars in liver disease.
[61] A. Dhillon,et al. Liver Transplantation in Cirrhotic Patients with Small Hepatocellular Carcinoma: An Analysis of Pre-Operative Imaging, Explant Histology and Prognostic Histologic Indicators , 2004, Digestive Surgery.
[62] O. Cummings,et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.
[63] H. Yoshimatsu,et al. Adiponectin protects LPS‐induced liver injury through modulation of TNF‐α in KK‐Ay obese mice , 2004 .
[64] M. Ingelman-Sundberg,et al. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis , 1998, Hepatology.
[65] G. Farrell. Signalling links in the liver: knitting SOCS with fat and inflammation. , 2005, Journal of hepatology.
[66] D. Befroy,et al. Mechanism of Hepatic Insulin Resistance in Non-alcoholic Fatty Liver Disease* , 2004, Journal of Biological Chemistry.
[67] D. Mitchell,et al. Focal manifestations of diffuse liver disease at MR imaging. , 1992, Radiology.
[68] K. Lindor,et al. A Pilot Trial of Pentoxifylline in Nonalcoholic Steatohepatitis , 2004, The American Journal of Gastroenterology.
[69] J. Lavine. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. , 2000, The Journal of pediatrics.
[70] A. Joseph,et al. Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. , 1991, Clinical radiology.
[71] I. Leclercq,et al. Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis. , 2003, Journal of hepatology.
[72] J. Crespo,et al. Are there Predictive Factors of Severe Liver Fibrosis in Morbidly Obese Patients with Non-alcoholic Steatohepatitis? , 2001, Obesity surgery.
[73] D. Schuppan,et al. Serum markers detect the presence of liver fibrosis: a cohort study. , 2004, Gastroenterology.
[74] F. Schaffner,et al. Nonalcoholic fatty liver disease. , 1986, Progress in liver diseases.
[75] A. Terano,et al. Plasma transforming growth factor‐β1 level and efficacy of α‐tocopherol in patients with non‐alcoholic steatohepatitis: a pilot study , 2001 .
[76] S. Caldwell,et al. Obesity and hepatocellular carcinoma. , 2004, Gastroenterology.
[77] J. Wang,et al. Body fat topography as an independent predictor of fatty liver. , 1993, Metabolism: clinical and experimental.
[78] P. Giral,et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. , 2005, Gastroenterology.
[79] G. Brandi,et al. Prevalence of and Risk Factors for Hepatic Steatosis in Northern Italy , 2000, Annals of Internal Medicine.
[80] H. Nomura,et al. Prevalence of fatty liver in a general population of Okinawa, Japan. , 1988, Japanese journal of medicine.
[81] J. Clore,et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. , 2001, Gastroenterology.
[82] G. Shulman,et al. Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[83] G. Marchesini,et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome , 2003, Hepatology.
[84] J. Marrero,et al. NAFLD may be a common underlying liver disease in patients with hepatocellular Carcinoma in the United States , 2002, Hepatology.
[85] H. Yoo,et al. Prevalence of Transaminase Abnormalities in Asymptomatic, Healthy Subjects Participating in an Executive Health-Screening Program , 2003, Digestive Diseases and Sciences.
[86] S. Fowler,et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002 .
[87] M. Yalnız,et al. The value of ultrasonography and computerized tomography in estimating the histopathological severity of nonalcoholic steatohepatitis. , 2005, Acta gastro-enterologica Belgica.
[88] H. Kim,et al. Insulin resistance and C‐reactive protein as independent risk factors for non‐alcoholic fatty liver disease in non‐obese Asian men , 2004, Journal of gastroenterology and hepatology.
[89] I. Wanless,et al. Fatty liver hepatitis (steatohepatitis) and obesity: An autopsy study with analysis of risk factors , 1990, Hepatology.
[90] K. Lindor,et al. Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction , 2004, Hepatology.
[91] M. Russell,et al. Cognitive Lifetime Drinking History in Nonalcoholic Fatty Liver Disease: Some Cases May Be Alcohol Related , 2004, American Journal of Gastroenterology.
[92] M. Flather,et al. The association of coronary calcium score and conventional cardiovascular risk factors in Type 2 diabetic subjects asymptomatic for coronary heart disease (The PREDICT Study) , 2004, Diabetic medicine : a journal of the British Diabetic Association.
[93] A. Lonardo,et al. Apolipoprotein synthesis in nonalcoholic steatohepatitis , 2002, Hepatology.
[94] M. Czaja. Liver injury in the setting of steatosis: Crosstalk between adipokine and cytokine , 2004, Hepatology.
[95] V. Paradis,et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: A potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis , 2001, Hepatology.
[96] A. McCullough. The Epidemiology and Risk Factors of NASH , 2007 .
[97] D. Joy,et al. Diagnosis of fatty liver disease: is biopsy necessary? , 2003, European journal of gastroenterology & hepatology.
[98] Mark Fishbein,et al. Hepatic MRI for Fat Quantitation: Its Relationship to Fat Morphology, Diagnosis, and Ultrasound , 2005, Journal of clinical gastroenterology.
[99] G. Farrell,et al. Etiopathogenesis of Nonalcoholic Steatohepatitis , 2001, Seminars in liver disease.
[100] A. Diehl,et al. Cytokines and the pathogenesis of non-alcoholic steatohepatitis , 2005, Gut.
[101] M. Weltman,et al. HFE mutations, hepatic iron, and fibrosis: Ethnic‐specific association of NASH with C282Y but not with fibrotic severity , 2002, Hepatology.
[102] M. Torbenson,et al. Dietary Composition and Nonalcoholic Fatty Liver Disease , 2004, Digestive Diseases and Sciences.
[103] J. Hoofnagle,et al. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002—June 10‐12, 2002 , 2002, Hepatology.
[104] S. Caldwell,et al. Subacute liver failure in obese women , 2002, American Journal of Gastroenterology.
[105] Jimmy D Bell,et al. Hepatic triglyceride content and its relation to body adiposity: a magnetic resonance imaging and proton magnetic resonance spectroscopy study , 2004, Gut.
[106] G. Marchesini,et al. A Randomized Controlled Trial of Metformin versus Vitamin E or Prescriptive Diet in Nonalcoholic Fatty Liver Disease , 2005, The American Journal of Gastroenterology.
[107] K. Lindor,et al. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study , 2001 .
[108] G. Farrell,et al. Insulin resistance, adiponectin, cytokines in NASH: Which is the best target to treat? , 2006, Journal of hepatology.
[109] Ayako Suzuki,et al. Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non‐alcoholic fatty liver disease , 2005, Liver international : official journal of the International Association for the Study of the Liver.
[110] G. Marchesini,et al. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. , 2005, The Journal of clinical endocrinology and metabolism.
[111] J. Pomposelli,et al. Cryptogenic cirrhosis: clinicopathologic findings at and after liver transplantation. , 2002, Human pathology.
[112] P. Giral,et al. Survival, liver failure, and hepatocellular carcinoma in obesity‐related cryptogenic cirrhosis , 2002, Hepatology.
[113] L. Friedman. Controversies in liver biopsy: Who, where, when, how, why? , 2004, Current gastroenterology reports.
[114] I. Leclercq,et al. Administration of the potent PPARα agonist, Wy‐14,643, reverses nutritional fibrosis and steatohepatitis in mice , 2004, Hepatology.
[115] H. Appelman,et al. Regression of hepatic steatosis in morbidly obese persons after gastric bypass. , 1995, American journal of clinical pathology.
[116] Eugene R. Schiff,et al. National Institutes of Health Consensus Development Conference Panel statement: Management of hepatitis C , 1997, Hepatology.
[117] T. Dwyer,et al. Alcohol consumption and the risk of alcohol related cirrhosis in women. , 1987, British medical journal.
[118] James G Kench,et al. Long‐term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C , 2003, Hepatology.
[119] K. Petersen,et al. Mitochondrial dysfunction and type 2 diabetes , 2005, Current diabetes reports.
[120] B. Neuschwander‐Tetri,et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions , 1999, American Journal of Gastroenterology.
[121] G. Farrell. Non‐alcoholic steatohepatitis: What is it, and why is it important in the Asia–Pacific region? , 2003, Journal of gastroenterology and hepatology.
[122] C. Alessandri,et al. Non‐alcoholic fatty liver syndrome: A hepatic consequence of common metabolic diseases , 2003, Journal of gastroenterology and hepatology.
[123] B. Neuschwander‐Tetri,et al. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR‐γ ligand rosiglitazone , 2003, Hepatology.
[124] B. Neuschwander‐Tetri,et al. Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference , 2003, Hepatology.
[125] H. Conjeevaram,et al. One-Year Intense Nutritional Counseling Results in Histological Improvement in Patients with Nonalcoholic Steatohepatitis: A Pilot Study , 2005, The American Journal of Gastroenterology.
[126] D. Purdie,et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life , 2004, Gut.
[127] D. Kleiner,et al. Pathologic features associated with fibrosis in nonalcoholic fatty liver disease. , 2004, Human pathology.
[128] B. Bacon,et al. Hepatic iron and nonalcoholic fatty liver disease , 1999, Hepatology.
[129] E. Kraegen,et al. Development of Muscle Insulin Resistance After Liver Insulin Resistance in High-Fat–Fed Rats , 1991, Diabetes.
[130] E. Roberts,et al. Steatohepatitis in children. , 2002, Best practice & research. Clinical gastroenterology.
[131] K. Batts,et al. Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease , 2001, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[132] S. Thung,et al. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. , 2004, Surgery.
[133] L. Burgart,et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial , 2004, Hepatology.
[134] R. Fisher,et al. Selection and outcome of living donors for adult to adult right lobe transplantation. , 2000, Transplantation.
[135] J. Hui,et al. Clear messages from sonographic shadows? Links between metabolic disorders and liver disease, and what to do about them , 2003, Journal of Gastroenterology and Hepatology.
[136] T. Saibara,et al. Bezafibrate for tamoxifeninduced non-alcoholic steatohepatitis , 1999, The Lancet.
[137] G. Kanel,et al. Proposal for a histological scoring and grading system for non‐alcoholic fatty liver disease , 2005, Liver international : official journal of the International Association for the Study of the Liver.
[138] J. George,et al. Fatty liver disease: NASH and related disorders , 2004 .
[139] I. Leclercq,et al. Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. , 2001, American journal of physiology. Gastrointestinal and liver physiology.
[140] G. Pacini,et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: Further evidence for an etiologic association , 2002, Hepatology.
[141] K. Lindor,et al. Management of NASH: Current and Future Perspectives on Treatment , 2007 .
[142] G. Gores,et al. Hepatic stellate cells and fibrosis progression in patients with nonalcoholic fatty liver disease. , 2005, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[143] R. Hanson,et al. The natural history of nonalcoholic steatohepatitis: A follow‐up study of forty‐two patients for up to 21 years , 1990, Hepatology.
[144] D. Koop,et al. Steatohepatitis induced by intragastric overfeeding in mice , 2005, Hepatology.
[145] R. Karim,et al. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome , 2002, Hepatology.
[146] G. Musso,et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis , 2003, Hepatology.
[147] J. Kench,et al. High sensitivity C‐reactive protein values do not reliably predict the severity of histological changes in NAFLD , 2004, Hepatology.
[148] S. Sanderson,et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. , 2005, Gastroenterology.
[149] L. Adams,et al. Recent concepts in non‐alcoholic fatty liver disease , 2005, Diabetic medicine : a journal of the British Diabetic Association.
[150] A. Cederbaum,et al. A high‐fat diet leads to the progression of non‐alcoholic fatty liver disease in obese rats , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[151] J. Hoofnagle,et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis , 2004, Hepatology.
[152] T. Saibara,et al. Bezafibrate for tamoxifen-induced non-alcoholic steatohepatitis. , 1999, Lancet.
[153] C. Mottin,et al. The Role of Ultrasound in the Diagnosis of Hepatic Steatosis in Morbidly Obese Patients , 2004, Obesity surgery.
[154] P. Ward,et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. , 1998, Gastroenterology.
[155] Ground Ke. Liver pathology in aircrew. , 1982 .
[156] K. Hasegawa,et al. Comparison of hepatocellular carcinoma patients with alcoholic liver disease and nonalcoholic steatohepatitis. , 2004, Alcoholism, clinical and experimental research.
[157] H. Tilg,et al. Adiponectin and its receptors in non-alcoholic steatohepatitis , 2004, Gut.